7/30/2013

The integrity of the pharmaceutical industry has been put into question with China's probe into GlaxoSmithKline's marketing practices. Finding a solution to Big Pharma's fraud habit should be a top priority of regulators worldwide, Erika Kelton writes.

Full Story:
Forbes

Related Summaries